TAKARATAKARA BIO INC.

Takara Bio Group Business

Takara Bio positions its Bioindustry Business as a stable revenue base providing research reagents, scientific instruments, and various contract services to universities and companies around the world, and now invests R&D funding into our Gene Therapy Business driving a company forward, aimed towards our future growth

Bioindustry Business

Takara Bio provides research reagents, scientific instruments and contract services for academic and corporate life sciences research and development.

Research Reagents and Scientific Instruments

Research reagents
Product Line-up

Promoting Strategies for Three Brands
Promoting Strategies for Three Brands

SMARTer<sup>®</sup>ICELL8<sup>®</sup>cx
SMARTer®ICELL8®cx

RetroNectin<sup>®</sup>
RetroNectin®

Since launching the first domestically produced restriction enzymes in 1979, we have continued to expand our product lineup through in-house development, and gone on to acquire the U.S.-based Clontech Laboratories (now Takara Bio USA, Inc.), a company that excels in molecular biological research, and Cellartis AB (now Takara Bio Europe AB), a company that manufactures reagents for research on stem cells such as iPS and ES cells. These acquisitions gave us ownership of the three brand names TaKaRa®, Clontech®, and Cellartis®.

  In 2007, we acquired WaferGen Bio-systems, which owns a single-cell analysis system (device), and Rubicon Genomics, which owns ultra-low input DNA analysis technology, allowing us to provide a wider range of products and services in the field of ultra-low input nucleic acid analysis, from basic research to industrial applications.



Clontech TaKaRa celllartis

Contract Services
(CDMO: Contract Development & Manufacturing Organization)

Center for Gene and Cell Processing
Center for Gene and Cell Processing(Kusatsu, Shiga)

In our contract development and manufacturing organization (CDMO) business, we leverage our genetic and cellular engineering technology gained through research reagent development, as well as our expertise in gene therapy clinical development to support development and manufacturing of regenerative medicine products.

  Our CDMO services provide a seamless package of regenerative medicine development support services and genetic testing support services such as genetic analysis for genome sequence and regenerative medicine products.



1. Contract Services for Developing Regenerative Medicine Products

Our contract services include not only development and manufacturing of viral vectors and gene-transduced cells for regenerative medicine products, which are the key to gene therapy, but also related services such as quality and safety testing and cell banking. We have already expanded into the Life Innovation Center Annex in Kawasaki, Kanagawa Prefecture, with the Center for Gene and Cell Processing, which is compliant with the GMP/GCTP quality control standard, as our core facility. We are working to further expand the research and manufacturing facilities at our headquarters.


Life Innovation Center (Kawasaki, Kanagawa)

2. Contract Gene Analysis Services

In addition to genetic testing support services such as human genome sequence analysis, comprehensive analysis of cancer-related genes, and intestinal flora analysis, we offer support services for advanced genetic engineering research using state-of-the-art technologies and equipment for next-generation sequencing and genome editing. We are also supporting Osaka University Hospital in their efforts to analyze genetic mutations in cancer patients to provide advanced cancer genomic medicine.


Click here for Product Information

Gene Therapy Business

Takara Bio is engaged in clinical development of gene therapies for cancer, etc., including the oncolytic virus canerpaturev (C-REV) and engineered T cell therapy.

Oncolytic Virus
Canerpaturev (Abbreviated to C-REV)

Canerpaturev (C-REV) is an attenuated strain of the herpes simplex virus type 1 (HSV-1) that exhibits antitumor activity upon local injection into a tumor due to tumor lysis. Treatment with C-REV also strengthens general immunity against cancer cells, and shows promise for producing an antitumor effect even in tumors not directly injected with C-REV. This type of virus is called an oncolytic virus. These viruses selectively replicate within and destroy tumor tissue without excessively damaging normal tissue, and are being developed as new treatment agents for cancers.

   Considering the new mechanism action of C-REV and the unmet medical needs for pancreatic cancer from clinical data obtained before, we will make great efforts on further development for pancreatic cancer. Currently, the phase I of C-REV in patients with unresectable pancreatic cancer is being conducted.



Engineered T Cell Therapy

Cell culture






1. siTCRTM Gene Therapy

T cell receptor (TCR) gene therapies involve collecting immune cells called T cells from a cancer patient, transducing TCR genes that have the ability to recognize cancer cells into those T cells, expanding the cells, and administering the cells back into the patinet. These transduced T cells gain the ability to specifically recognize and attack cancer cells, and are thus utilized in cancer therapy. At Takara Bio, we are also developing siTCRTM gene therapies that use our propriatary siTCRTM vector technology, which we believe will improve treatment efficacy.

   We are currently conducting phase I/II clinical trials of NY-ESO-1• siTCRTM gene therapy for synovial sarcoma in Japan.


Cell culture

2. CAR Gene Therapy

Chimeric antigen receptors (CARs) are made by artificially combining T cell surface antibodies that recognize cancer cells with cytotoxic components derived from T cell receptors. CAR gene therapies involve infusion of T cells transduced with CAR genes into the patient, allowing these genetically engineered T cells to specifically recognize and attack cancer cells.

   We are currently conducting phase I/II clinical trials of CD19• CAR gene therapy for adult acute lymphoblastic leukemia in Japan.

Proprietary Technology Advancing Gene Therapy

Genetically engineered T cell therapies such as TCR and CAR therapies involve a process of collecting T cells from a patient's body and transducing them with therapeutic genes that increase the ability of the cells to attack cancer. In this process, it is important to enhance transduction effiency and utilize expansion culture for efficiient cell expansion.
   Our propriatary RetroNectin® technology is widely used in this process, and we out-license it to many companies and research institutes developing gene therapy products.


Clieck here for Detail Information

Business Outline

return to top

Our website uses cookies to ensure that we give you the best user experience.Read more
By continuing to use our site, you consent to our cookies.

Accept